tradingkey.logo

Evoke Pharma Inc

EVOK
11.000USD
0.0000.00%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
18.95MValor de mercado
PerdaP/L TTM

Mais detalhes de Evoke Pharma Inc Empresa

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.

Informações de Evoke Pharma Inc

Código da empresaEVOK
Nome da EmpresaEvoke Pharma Inc
Data de listagemSep 25, 2013
CEOD'Onofrio (Matthew J)
Número de funcionários3
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 25
Endereço420 Stevens Avenue
CidadeSOLANA BEACH
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92075
Telefone18583451494
Sitehttps://evokepharma.com/
Código da empresaEVOK
Data de listagemSep 25, 2013
CEOD'Onofrio (Matthew J)

Executivos da empresa Evoke Pharma Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+1318.00%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-1.00%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
--
-27.00%
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
--
-133.00%
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Mr. Mark A. Kowieski
Mr. Mark A. Kowieski
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+1318.00%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-1.00%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
--
-27.00%
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--

Detalhamento da receita

FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: qua, 4 de fev
Atualizado em: qua, 4 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
DRW Securities, LLC
1.38%
Two Sigma Investments, LP
0.61%
D'Onofrio (Matthew J)
0.57%
Outro
79.48%
Investidores
Investidores
Proporção
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
DRW Securities, LLC
1.38%
Two Sigma Investments, LP
0.61%
D'Onofrio (Matthew J)
0.57%
Outro
79.48%
Tipos de investidores
Investidores
Proporção
Individual Investor
10.59%
Investment Advisor
10.08%
Hedge Fund
0.61%
Research Firm
0.01%
Outro
78.71%

Participação acionária institucional

Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
25
502.38K
22.98%
--
2025Q3
26
502.38K
25.40%
+260.79K
2025Q2
25
242.44K
26.58%
-10.18K
2025Q1
28
252.99K
24.26%
-109.24K
2024Q4
30
218.46K
24.86%
-81.81K
2024Q3
31
208.32K
29.69%
-54.34K
2024Q2
31
262.66K
432.25%
-959.00
2024Q1
39
263.62K
30.12%
+47.85K
2023Q4
36
5.70K
3.76%
+99.00
2023Q3
40
5.65K
7.83%
+642.00
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Klein (Roger M.)
163.00K
9.46%
+163.00K
--
Nov 04, 2025
Bleichroeder LP
146.40K
8.5%
+77.64K
+112.94%
Sep 30, 2025
DRW Securities, LLC
23.74K
1.38%
+23.74K
--
Sep 30, 2025
Two Sigma Investments, LP
10.44K
0.61%
+10.44K
--
Sep 30, 2025
D'Onofrio (Matthew J)
9.82K
0.57%
+1.32K
+15.50%
Mar 24, 2025
Kowieski (Mark A.)
4.92K
0.29%
+4.92K
--
Mar 24, 2025
Osaic Holdings, Inc.
3.01K
0.17%
+3.01K
--
Sep 30, 2025
Gonyer (David A)
2.36K
0.14%
-1.00
-0.04%
Mar 24, 2025
Garner (Cam L)
2.33K
0.14%
-1.00
-0.04%
Mar 24, 2025
Northwestern Mutual Capital, LLC
272.00
0.02%
+272.00
--
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
Data
Data ex-dividendo
Tipo
Proporção
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
KeyAI